Clasp Therapeutics Secures $150M to Advance Personalized Cancer Immunotherapies

Clasp Therapeutics, a promising biotechnology startup headquartered in Cambridge, Massachusetts, and Rockville, Maryland, has emerged on the scene with a formidable goal: to develop a suite of next-generation immunotherapies tailored to combat hard-to-treat tumors. Launched on March 20, 2024, with an impressive $150 million in Series A financing, Clasp has captured the attention of industry giants and investors alike.

Led by CEO Robert Ross, whose track record includes successful ventures in the oncology space, Clasp has attracted significant backing from prominent investors such as Novo Holdings, Third Rock, and Catalio, along with support from the American Cancer Society's philanthropic fund and others. Ross's previous experience at Surface Oncology, acquired by Coherus, and bluebird bio positions him well to steer Clasp toward success.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

At the heart of Clasp's innovative approach lies the development of T cell engagers (TCE), a burgeoning area in cancer therapeutics. TCEs, which facilitate a destructive immune response against tumors, have garnered attention in the industry. Notably, Gilead recently struck a substantial deal with Merus for its T-cell engager antibodies, signaling growing interest and investment in this field.

What sets Clasp apart is its novel design targeting proteins inside cancer cells rather than on their surface. By grabbing onto peptides displayed by specialized human leukocyte antigen (HLA) molecules, Clasp's TCEs aim to minimize off-target effects associated with traditional approaches. This precision targeting, coupled with personalized treatment tailored to specific mutations and patient HLA types, holds the promise of combining the efficacy of personalized therapy with the convenience of off-the-shelf treatments.

The infusion of $150 million from its Series A financing is poised to propel Clasp's pioneering candidates through early clinical development stages, gathering crucial proof-of-concept data along the way. CEO Robert Ross emphasizes the importance of early efficacy data in today's competitive oncology biotech landscape, where demonstrating activity early on is paramount for success.

While Clasp's initial target and timeline for IND submission have not been disclosed, the company's ambitious vision and innovative approach position it as a key player in the evolving landscape of cancer immunotherapy. With personalized treatments on the horizon, Clasp Therapeutics stands at the forefront of advancing cancer care, offering hope for patients with hard-to-treat tumors.